Clinical-stage biopharmaceutical company developing novel, oral medicines designed to treat a range of rare diseases, including primary immunodeficiency diseases and rare cancers.
- Year invested 2017
- Investment Stage Public/PIPES
- Sectors
- Investment Status Current
- Associated Team
- Website x4pharma.com
- Company Status IPO/Public (NASDAQ: XFOR)